

RESEARCH ARTICLE

Modern Strategies for Correcting Metabolic Disorders in Cardiorenal Syndrome

Khudoyberdieva G.A.

Tashkent State Medical University, Republican Specialized Scientific and Practical
Medical Center of Nephrology and Kidney Transplantation, Uzbekistan

Abstract: The article discusses metabolic disorders such as insulin resistance, hyperglycemia, and dyslipidemia in patients with chronic heart failure (CHF) and chronic kidney disease (CKD). These disorders play a key role in the progression of both diseases. The article analyzes modern therapeutic approaches, including the use of SGLT2 inhibitors and mineralocorticoid receptor antagonists, as well as the importance of personalized therapy.

Key words: Cardiorenal syndrome, metabolic disorders, chronic heart failure, chronic kidney disease, SGLT2 inhibitors.

INTRODUCTION

Chronic heart failure and chronic kidney disease are serious conditions that often coexist and exacerbate each other. The development of metabolic disorders, such as hyperglycemia and insulin resistance, further complicates the course of these diseases. Controlling these metabolic parameters becomes a key aspect of patient management.

Metabolic Disorders in CHF and CKD

Studies have shown that hyperglycemia and insulin resistance play a leading role in the pathogenesis of CHF and CKD. Cooper et al. (2021) found that the frequency of metabolic disorders is higher in patients with both CHF and CKD than in patients with only one of these diseases, contributing to a worse prognosis.

Special attention is given to the relationship between hyperglycemia and worsening kidney function. The study by Heerspink et al. (2021) showed that controlling glucose levels and reducing insulin resistance can significantly improve outcomes in patients with CKD. However, despite these findings, most patients still suffer from inadequate control of metabolic parameters.

Heart failure (HF) is a significant public health problem worldwide. Fibrosis, leading to structural changes in the myocardium and

vascular wall, plays a key role in the progression of HF. In this regard, the search for pathogenetically based therapy aimed at slowing myocardial fibrosis is relevant. Results from the EMPA-REG OUTCOME study showed that glucose-lowering drugs, particularly sodium-glucose cotransporter 2 (SGLT2) inhibitors, positively affect the course of HF by reducing cardiovascular mortality and hospitalizations for HF decompensation. Antifibrotic properties of SGLT2 inhibitors have been identified in large studies. This review presents the results of experimental studies of SGLT2 inhibitors in animals, describing the mechanisms of their antifibrotic action on the cardiovascular system. Further study of SGLT2 inhibitors in clinical trials is relevant for identifying and correcting the pathogenetic mechanisms of myocardial fibrosis.

Mineralocorticoid receptor antagonists, such as eplerenone, also play an important role in the treatment of patients with chronic heart failure (CHF) and chronic kidney disease (CKD). Bakris et al. (2021) demonstrated that the use of eplerenone leads to a significant reduction in the risk of mortality and hospitalizations in these patients.

RESEARCH ARTICLE

Special attention is given to the relationship between hyperglycemia and worsening kidney function. The study by Heerspink et al. (2021) showed that controlling glucose levels and reducing insulin resistance can significantly improve outcomes in patients with CKD. However, despite these findings, most patients still suffer from inadequate control of metabolic parameters.

Modern Treatment Approaches

Current therapeutic approaches include the use of SGLT2 inhibitors, such as empagliflozin and dapagliflozin, which not only improve glycemic control but also have a positive effect on renal and cardiovascular outcomes. The study by Zannad et al. (2021) showed that empagliflozin reduces the risk of cardiovascular events by 25% and the risk of kidney failure by 17%.

Mineralocorticoid receptor antagonists, such as eplerenone, also play an important role in the treatment of patients with CHF and CKD. Bakris et al. (2021) demonstrated that the use of eplerenone leads to a significant reduction in the risk of mortality and hospitalizations in these patients.

In addition to SGLT2 inhibitors, mineralocorticoid receptor antagonists (MRAs) also provide significant therapeutic benefits in patients with chronic heart failure (CHF) and chronic kidney disease (CKD). A study by Bakris et al. (2021) found that eplerenone, one of the most studied MRAs, significantly reduces the risk of cardiovascular mortality and the frequency of hospitalizations in patients with CHF and CKD, confirming its role in preventing complications associated with fibrosis and inflammation in renal and cardiac tissues.

A study by Pitt et al. (2020) also showed that the use of spironolactone, another MRA, improves diastolic function and reduces the severity of cardiac fibrosis in patients with CHF and preserved ejection fraction. Spironolactone reduces levels of fibrosis biomarkers, such as NT-proBNP, and improves clinical symptoms, enhancing patients' quality of life. These data indicate the need for wider use of MRAs to improve prognoses in patients with CHF,

especially those with preserved ejection fraction.

The study by Agarwal et al. (2019) showed that eplerenone therapy combined with standard therapy for CKD significantly reduces the level of albuminuria, indicating its positive effect on renal function. These results underscore the need for further research to clarify the mechanism of action of MRAs on renal and cardiovascular fibrosis and to improve treatment outcomes in patients with CHF and CKD.

Besides SGLT2 inhibitors, mineralocorticoid receptor antagonists (MRAs) also play an important role in slowing the progression of fibrosis and improving clinical outcomes in patients with heart failure (HF) and chronic kidney disease (CKD). A study by Bakris et al. (2021) demonstrated that the use of eplerenone, one of the MRAs, contributes to a significant reduction in the risk of cardiovascular mortality and hospitalization rates in patients with HF and CKD. These results confirm the importance of mineralocorticoid receptor blockade in improving myocardial condition and preventing progressive deterioration of kidney function in such patients.

Another significant study, conducted by Pitt et al. (2019), showed that the use of another MRA, spironolactone, in patients with HF and preserved ejection fraction (HFpEF) is associated with reduced severity of cardiac fibrosis and improved diastolic function. Spironolactone reduced levels of biomarkers associated with fibrosis, such as NT-proBNP, and improved patients' quality of life. These data indicate the potential therapeutic benefits of using MRAs to prevent fibrotic changes in the heart and improve long-term outcomes in HF, especially in patients with HFpEF.

Personalized Therapy

The use of pharmacogenetic analyses to select optimal therapeutic strategies is becoming increasingly relevant. For example, research by Thomas et al. (2021) showed that pharmacogenetics can predict the response to SGLT2 inhibitors, facilitating treatment personalization and reducing side effects.

RESEARCH ARTICLE

Remote patient monitoring and the use of artificial intelligence for data analysis also play an important role in modern medical practice. These technologies allow for timely adjustment of therapy and improvement of treatment outcomes.

CONCLUSION

Metabolic disorders in patients with CHF and CKD require a comprehensive approach to treatment. Modern drugs, such as SGLT2 inhibitors and mineralocorticoid receptor antagonists, combined with personalized approaches, demonstrate high effectiveness in reducing cardiometabolic risk. Future research should focus on optimizing therapeutic strategies and developing new treatment methods.

REFERENCES

1. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Ruilope LM, et al. Cardiovascular and kidney outcomes with finerenone in patients with CKD and type 2 diabetes: FIDELIO-DKD trial. *Kidney Int.* 2019;96(2):469-481. doi:10.1016/j.kint.2019.11.028.
2. Bakris G.L. et al. (2021). Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes. *New England Journal of Medicine*, 383, pp. 2219-2229.
3. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med.* 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956.
4. Bhatt D.L. et al. (2021). Sotagliflozin Reduces Heart Failure Events in Patients with Diabetes and CKD Regardless of Albuminuria Status. *Journal of the American College of Cardiology*, 78(1), pp. 101-110.
5. Cooper M.E. et al. (2021). The Interplay between Diabetes, Heart Failure, and chronic kidney disease: Mechanisms and Therapeutic Implications. *Diabetologia*, 64(2), pp. 271-281.
6. Filippatos G., Anker S.D., Böhm M. et al. (2022). Benefits of Finerenone to Improve Outcomes in Patients with Kidney Disease Diabetes. *Journal of the American College of Cardiology*, 79(12), pp. 1508-1518.
7. Heerspink H.J.L. et al. (2021). Rationale and Design of the EMPA-KIDNEY Study. *Clinical Journal of the American Society of Nephrology*, 16(1), pp. 124-136.
8. Jardine M.J. et al. (2021). The Role of Finerenone in Cardiorenal Protection. *Lancet Diabetes & Endocrinology*, 9(7), pp. 649-659.
9. Kemp C.D., Conte J.V. (2021). The Pathophysiology of Heart Failure. *Cardiovascular Pathology*, 30(2), pp. 79-89.
10. McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. (2021). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *New England Journal of Medicine*, 385(16), pp. 1451-1461.
11. Perkovic V. et al. (2021). Cardiorenal Outcomes with Finerenone in Patients with CKD and T2D. *New England Journal of Medicine*, 385, pp. 2252-2263.
12. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Greenlaw N, et al. Safety and tolerability of spironolactone in patients with heart failure and preserved ejection fraction: The TOPCAT trial. *JAMA Cardiol.* 2020;5(6):1-9. doi:10.1001/jamacardio.2020.0505.
13. Pitt B. et al. (2021). The Role of SGLT2 Inhibitors in Reducing Cardiovascular and Renal Events in Patients with Chronic Kidney Disease. *American Journal of Cardiology*, 136, pp. 122-130.
14. SwedeHF Investigators (2022). Prevalence and Prognostic Impact of Kidney Disease on Heart Failure Patients. *Open Heart*, 7(2).
15. Thomas M.C., Cooper M.E., Zimmet P. (2021). Changing Epidemiology of Type 2 Diabetes Mellitus and Associated Chronic Kidney Disease. *Nature Reviews Nephrology*, 17(4), pp. 220-232.
16. Verma S. et al. (2021). DAPA-HF Trial: Efficacy of Dapagliflozin in Heart Failure Patients with and without Diabetes. *Circulation*, 143(13), pp. 2143-2153.
17. Wheeler D.C. et al. (2021). Effects of dapagliflozin on cardiovascular and kidney outcomes in patients with CKD. *European Heart Journal*, 42(13), pp. 1213-1222.

RESEARCH ARTICLE

18. 18. Zannad F. et al. (2021). Cardiovascular and Renal Outcomes with Empagliflozin in Patients with Heart Failure. New England

Journal of Medicine, 385(20), pp. 1883-1893.